MYDEKLA

Mydekla is available has tablet form and belongs to class of antiviral medication.
Mydekla possess antiviral activity and will inhibits the NS5Adomain of hepatitis C virus (HCV)
Usually it is not regard as a monotherapy treatment but used with the combination of other antiviral drugs like Sofosbuvir and ribavirin.
During the treatment are exotic will increases in serum enzymes level, it has sufficiently suspected in case of clinically apparent hepatic injury like jaundice.


INDICATIONS

Mydekla an anti viral medication, used to treat hepatitis C virus from replicating in the body. It is also used to treat genotype III chronic hepatitis C virus (HCV) in adolescent without cirrhosis.
Mydekla not used separately, it should be combined with Sofosbuvir. Mydekla Tablet is used in combination form only, with other anti viral medications such as Sofosbuvir, interferon and ribavirin for the treatment of hepatitis C infection.


CONTRAINDICATIONS

Mydekla with ribavirin contraindicated to pregnancy condition
Hypersensitivity reaction occur
Concurrent use of CYP3A inducers strong with Mydekla , contraindicated to the patients

daclatasvir60mg.ne-slider-image6.jpg

Brand Name: Mydekla
Composition: Daclatasvir dihydrochloride tablets
Strength: 60mg
Dosage form: Tablet
Manufactured by: Mylan
Packing: 28 tablets in plastic container

BUY NOW !!

ABOUT MYDEKLA

daclatasvir60mgdosage-1

Mydekla not used alone, it is combined with Sofosbuvir.
Genotype I:
Without cirrhosis and compensated cirrhosis: Mydekla with Sofosbuvir for 12 weeks
Decompensated cirrhosis: Mydekla with Sofosbuvir combined with ribavirin for 12 weeks.
Genotype III:
Without cirrhosis: Mydekla with Sofosbuvir for 12 weeks
Compensated or decompensated cirrhosis: Mydekla with Sofosbuvir combined with ribavirin for 12 weeks.


Dose modification of Mydekla:

Strong CYP3A inhibitors and certain Anti retroviral agents: Dosage of Mydekla is 30mg orally as single dose
Moderate CYP3A inducers and Nevirapine: dose should be 90mg orally
Strong CYP3A inducers: Mydekla is contraindicated.
OVERDOSAGE: Mydekla overdose has no particular antidote. Treatment will consist of supportive measures, involving monitoring of vitals and patient clinical status observation.

daclatasvir60mgdosage-2

Mydekla is a direct acting anti viral agent which is used to cure chronic symptomatic HCV infection, with combination of Sofosbuvir .
Mydekla NS5A protein inhibitor
Sofosbuvir - direct acting nucleotide analogue inhibitor, NS5B polymerase inhibitor.
Both leading drug undergoes to inhibit polymerase enzyme which is responsible for viral replication.
Blocks the action of HCV NS5B polymerase leads to chain termination.
Ribavirin, it is a synthetic ribonucleic analogue which is incorporated into RNA blocking RNA synthesis. When ribavirin is used alone, it does not have anti viral property.


Absorption:
The peak serum concentration of Mydekla occurred within 2 hours.
Distribution:
Human plasma protein binding of Mydekla is approximately 99%. The volume of distribution is 47L.
Metabolism:
CYP3A, it is substrate of Mydekla combined with CYP3A4 (CYP isoform) essential for metabolism.
Excretion:
The terminal half life period of Mydekla is around 12 to 15 hours.

daclatasvir60mgdosage-3.jpg

→ HMG CoA reductase: increase the effect of concentration of these lipid lowering drugs
Mydekla is an inhibitor of P-glycoprotein transporter, organic anion transporting polypeptide and breast cancer resistance protein; taking Mydekla, may elevate exposure to these drugs, which prolong the therapeutic effect
→ Interaction with Proteases inhibitors will have high Mydekla effect of concentration .
→ Strong inducers of CYP3A causes decreased therapeutic effect of Mydekla
→ Strong CYP3A inhibitors: increase the effect of concentration of Mydekla
PRECAUTIONS
Mydekla combination with amiodarone and Sofosbuvir then use with caution because it will cause bradycardia
If patients while on treatment with Mydekla they have heart disease, hepatic impairment, hepatitis B reactivation occurs after discontinuation then care should be taken and give piror information to the doctor .

daclatasvir60mgdosage-4

PREGNANCY
Pregnancy category is B while Mydekla using as alone treatment, safe to use during pregnancy but should get advice from medical practitioner.
During combination with other antiviral drug then pregnancy categories with ribavirin-X; causes severe ill effects like fetal harm even to death

LACTATION Breast feeding is safe during monotherapy but in combination with ribavirin breast feeding is not recommended.

STORAGE:
Mydekla tablets containers are stored at 25oC to 77oF
Keep away from heat, moisture and heat.
Store the drug in its own container
Dispose the drug by asking advice from pharmacist.

MISSED DOSE:
If patient fail to take the dose of Mydekla tablet, must consult with physician and take the missed dose within the time.
Otherwise the missed dose should be skipped and follow the regular dosing schedule.
Do not take extra dose at same time.

daclatasvir60mgdosage-4

Serious side effects Chest pain or discomfort, lightheadedness, dizziness, or fainting, slow or irregular heartbeat, unusual tiredness

More common Headache ,nausea
Less common :
Diarrhea
Nervous system
Headache Dizziness, migraine, somnolence



Prescription Medication Policy


1. daclatasvir60mg.net a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. daclatasvir60mg.net will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the daclatasvir60mg.net is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. daclatasvir60mg.net requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from daclatasvir60mg.net
6. At daclatasvir60mg.net, a Caregiver can order prescription medicines on your behalf.


DISCLAIMER


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.